NeuroOne Medical Technologies Corporation has announced a robust financial performance for the third quarter of fiscal year 2026, showcasing significant expansion in product revenue and new orders. Despite facing some manufacturing limitations, the company has made considerable strides in its product development pipeline and strategic initiatives, including achieving crucial international certifications and advancing clinical studies for its innovative medical devices. The results highlight NeuroOne's commitment to improving patient outcomes through advanced neurosurgical technologies and expanding its global market presence.
On Thursday, August 13, 2026, NeuroOne Medical Technologies Corporation (NMTC) disclosed its financial results for the third quarter of fiscal year 2026 during its earnings call. The company's leadership team, including CEO Dave Rosa, CFO Chris Volker, and CBO Dave Wambecke, presented key figures and strategic insights. Product revenue for the quarter reached $2.0 million, marking a 16% increase compared to the $1.7 million reported in the third quarter of fiscal 2025. This growth was primarily fueled by heightened demand for OneRF products.
A notable achievement was the substantial increase in new product orders, which soared by 43% year-over-year to $2.7 million. This surge in orders exceeded the company's current manufacturing capabilities, resulting in a backlog of $1.7 million by June 30, 2026. NeuroOne anticipates aggregate product orders of approximately $11.2 million for the full fiscal year 2026, with recognized revenue projected to range between $9.2 million and $10.5 million, contingent on manufacturing and shipment timelines. To address these capacity challenges, the company is actively working to qualify a second, larger manufacturing site, expected to be operational in early 2027.
Further enhancing its market position, NeuroOne achieved ISO 13485 certification, an international quality management standard essential for global market entry. This certification will facilitate the international commercialization of its OneRF Brain Ablation System, OneRF Trigeminal Neuralgia Ablation System, and Evo Cortical and sEEG diagnostic product lines, in collaboration with distribution partner Zimmer Biomet. The company plans to strategically target international geographies that align with existing customer relationships and favorable economic conditions, while also exploring independent partnerships for other regions.
In terms of product development, the OneRF Brain Ablation System continued its strong performance, alongside significant clinical advancements. A study published in The Journal of Neurosurgery, conducted by the Mayo Clinic, demonstrated that NeuroOne's OneRF Brain Ablation System could be safely used in patients with existing neuromodulation devices, expanding the treatable patient population. The OneRF Trigeminal Nerve Ablation System also garnered positive attention, with a patient sharing a compelling success story on Cleveland 19 News, highlighting the life-changing potential of the therapy for individuals suffering from severe facial pain.
NeuroOne's drug delivery system, StereoCED, is also progressing rapidly. Designed as a robotic-assisted platform, StereoCED aims to streamline intracranial drug delivery by leveraging existing neurosurgical workflows, potentially reducing procedure times from 8-12 hours and avoiding the need for hospitals to acquire entirely new robotic systems. The company plans to initiate investigational human clinical studies for StereoCED by the end of September and anticipates preliminary data from ongoing animal studies with the University of Minnesota and Mayo Clinic this fall.
The company's Basivertebral Nerve Ablation (BVNA) System for back pain management also saw continued development, with completed user design requirements and preclinical testing underway. NeuroOne expects to submit for FDA 510(k) clearance for the BVNA system in the second half of calendar 2027. Despite current manufacturing lead times of up to six months and potential impacts on product mix responsiveness, NeuroOne remains optimistic about its future growth, emphasizing its innovative product portfolio and strategic market expansion plans.
NeuroOne's third-quarter fiscal 2026 earnings call painted a picture of a medical technology company experiencing strong growth in product sales and expanding its global footprint. Despite grappling with manufacturing bottlenecks, the firm's leadership outlined clear strategies to overcome these challenges, including the establishment of a second production facility and strategic international partnerships. The advancements in its core product lines, coupled with promising developments in drug delivery and pain management systems, underscore NeuroOne's commitment to innovation and its potential for continued expansion in the medical device market.
